Publications by authors named "Karl S Hurst-Wicker"
Article Synopsis
- Researchers conducted a clinical trial using a recombinant vaccinia virus (rV-B7.1) to treat metastatic melanoma by intralesional vaccination, addressing the challenges of local T cell tolerance in the melanoma microenvironment.
- The trial involved 12 patients and reported minimal side effects like low-grade fever and fatigue, leading to partial response in 1 patient and disease stabilization in 2 others, with one surviving without disease for over 59 months post-vaccination.
- The findings showed increased antibody and T cell responses post-vaccination, suggesting that rV-B7.1 may effectively alter the local tumor environment and improve immune responses against melanoma.
Recombinant interleukin-2 (IL-2) has demonstrated antitumor activity and durable clinical responses in patients with metastatic melanoma. Careful screening and selection of appropriate patients has improved the safety profile of IL-2 administration. Gross hematuria would ordinarily preclude the safe delivery of IL-2.
View Article and Find Full Text PDF